Kristin Taylor
Gynecologic Oncology · Everett, WANPI 1467748855
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,150 of the $12,103 with a category attached, or 83.9%. AbbVie accounts for 93.8% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $11,488 and has fallen 97.4% since, to $301 in 2025.
Across 25 payments — averaging $484.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- GSK$313
- AstraZeneca$214
- Tesaro, Inc.$157
- Intuitive Surgical$63
What the payments were for
- Consulting fees$10,15084%
- Travel & lodging$7616%
- Food & beverage$9138%
- Education$2792%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 11 | $11,356 |
| GSK | 7 | $313 |
| AstraZeneca | 2 | $214 |
| Tesaro, Inc. | 2 | $157 |
| Intuitive Surgical | 3 | $63 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,103 in reported general payments places this provider in the 85th percentile of 36 gynecologic oncology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Megestrol Acetate | 16 | $756 |
| Estradiol | 15 | $673 |
| Prochlorperazine Maleate | 14 | $190 |
| Ondansetron Hcl | 11 | $186 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Everett
- Chirag ShahSeattle$732K
- Fernanda MusaSeattle$120K
- Bobbie RimelSeattle$41K
- Nicole FlemingSeattle$20K
- Renata UrbanSeattle$7K
- Robert OreLacey$5K
- Christopher BreedPuyallup$5K
- Amy BrockmeyerSeattle$4K
- Elizabeth GrosenSpokane$3K
- Weiya WyshamVancouver$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.